| 标题 |
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet 作者:Kristian Reich; Kim Papp; Andrew Blauvelt; Richard G. Langley; April W. Armstrong; et al 出版日期:2021-02-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)